Beauty

Shiseido to Sell Aupres China Business to IDG Capital-Led Consortium

The binding agreement covers Shiseido Liyuan Cosmetics, its Beijing factory and the Aupres brand, with completion targeted for late 2026 to early 2027 pending regulatory clearance.

Mira SolenNovember 19, 20265 min read2 views

Unbranded skincare bottles and jars on a stone counter, one being placed into an open shipping box, with a softly blurred factory floor behind.

Shiseido has signed a binding agreement to sell Shiseido Liyuan Cosmetics (SLC), the subsidiary that manufactures and markets the Aupres brand in China, to an investor consortium led by Hong Kong-headquartered private equity firm IDG Capital. The Japanese group will transfer the entire company; financial terms were not disclosed. The transaction is expected to close between the fourth quarter of 2026 and the first quarter of 2027, subject to regulatory approvals including in China.

What changes hands

SLC was established in 1991 as a joint venture with Beijing Liyuan, a subsidiary of Yiqing Group, which is owned by the Beijing Municipal Government. The company has sold Aupres, positioned as a C-beauty brand, since 1994. The sale covers SLC's Beijing factory and production equipment, not only the brand business.

Under the agreed structure, funds managed by IDG Capital will hold 95% of the equity through two special purpose vehicles. A limited partnership enterprise set up mainly by SLC's incoming management team will hold the remaining 5%, giving the new leadership a direct stake in the standalone business.

Full ownership before the exit

The existing joint venture agreement was due to expire in December 2026, and the parties agreed not to renew it. Instead, Shiseido acquired Beijing Liyuan's 35% stake on September 1, 2026, taking full ownership of SLC ahead of the sale. The sequence means the buyer receives 100% of the company rather than a partial joint venture interest.

The strategic case

Shiseido frames the divestment as part of its 2030 Medium-Term Strategy, which targets improved profitability and capital efficiency. The company says it wants to concentrate management resources on the areas where it holds its strongest competitive advantage, and on priority brands and higher-growth opportunities.

According to Shiseido, the Aupres business requires continued investment in product innovation and digital capabilities — spending the group now intends to redirect. The company describes China as a strategically important and attractive market whose competitive landscape continues to evolve amid rapid e-commerce expansion, changing consumer behavior and the emergence of diverse market participants.

Transition arrangements

Shiseido believes independent operation under IDG will support SLC's sustainable growth and brand value. To smooth the handover, it will license the intellectual property rights the buyer needs to run the business. For a specified period after the transfer, Shiseido will also provide support on new product development, technical assistance for stable supply of existing products, and continued supply of raw materials and selected products. The company says these arrangements are meant to preserve SLC's innovation capability, product quality and business continuity.

Financial backdrop

The sale was announced days after Shiseido reported a 124.3% rise in core operating profit for the third quarter of 2026, to ¥67.5 billion (US$422.13 million). The company attributed the recovery to restructuring, cost reductions and improved margins rather than strong product demand; like-for-like sales grew 0.7%. On the back of those results, Shiseido lifted its full-year core operating profit forecast from ¥59 billion (US$433 million) to ¥87 billion (US$546 million).